UR Dermatology at College Town
Welcome,         Profile    Billing    Logout  
 7 Trials 
20 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Beck, Lisa
LEADS, NCT05436535: Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

Active, not recruiting
4
431
US
Dupilumab, Dupixent, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide, Hydrocortisone, Vanicream- Active, Vanicream- Experienced Dupilumab
National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
04/25
10/25
NCT05551793: Regeneron AA Multicenter (Dupilumab)

Recruiting
2
68
US
Dupilumab, Placebo
Emma Guttman, Regeneron Pharmaceuticals
Alopecia Areata
12/26
12/27
NCT06504160: Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

Recruiting
1/2
86
US
ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel
National Institute of Allergy and Infectious Diseases (NIAID), Atopic Dermatitis Research Network (ADRN), Rho Federal Systems Division, Inc., PPD, Thermo Fisher Scientific Inc.
Atopic Dermatitis
10/26
11/26
NCT04170244: Study of Skin Microbiome in AD and PS Patients

Recruiting
N/A
240
US
AD subject visit sampling procedures, PS subject visit sampling procedures, Healthy control visit sampling procedures
University of Rochester
Atopic Dermatitis, Psoriasis
04/26
04/26
Singer, Giselle
NCT06336343: Bimekizumab in Plaque Psoriasis

Recruiting
4
60
US
Bimekizumab
Icahn School of Medicine at Mount Sinai, UCB Pharma, Psoriasis Treatment Center of Central New Jersey
Plaque Psoriasis
10/25
10/25
NCT04988022: Dupilumab in the Treatment of Keloids

Active, not recruiting
4
44
US
Dupilumab, Dupixent, Placebo
Icahn School of Medicine at Mount Sinai, Regeneron Pharmaceuticals, Sanofi
Keloid
06/25
06/25
NCT05608499: Duobrii Treatment of Acne Keloidalis Nuchae (AKN)

Active, not recruiting
3
30
US
Duobrii, halobetasol propionate and tazarotene, Placebo, Bryhali, halobetasol propionate
Icahn School of Medicine at Mount Sinai, Bausch Health Americas, Inc.
Acne Keloidalis Nuchae, AKN
07/25
07/25
NCT05787860: Ruxolitinib in Seborrheic Dermatitis

Completed
2
45
US
Ruxolitinib 1.5% Cream
Icahn School of Medicine at Mount Sinai, Incyte Corporation
Seborrheic Dermatitis
01/24
01/24
NCT05399368: An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

Terminated
2
229
Canada, US
RPT193, Placebo
RAPT Therapeutics, Inc.
Atopic Dermatitis
05/24
05/24
NCT06373458: Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy

Recruiting
2
30
US
Ritlecitinib
Icahn School of Medicine at Mount Sinai, Pfizer
Keloid
03/26
05/26
NCT06532136: Deucravacitinib Rosacea

Withdrawn
2
33
US
Deucravacitinib, Placebo
Icahn School of Medicine at Mount Sinai, Bristol-Myers Squibb
Papulopustular Rosacea
01/26
01/26
NCT05549934: Ritlecitinib for Cicatricial Alopecia

Completed
2
50
US
PF-06651600, Ritlecitinib
Emma Guttman, Pfizer
Cicatricial Alopecia
03/25
03/25
NCT06013371: PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea

Terminated
2
32
US
PF-07038124, Placebo Ointment
Icahn School of Medicine at Mount Sinai, Pfizer
Seborrheic Dermatitis, Papulopustular Rosacea
02/25
02/25
NCT06795373: Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria

Recruiting
2
20
US
Ritlecitinib, PF-06651600
Ahuva D Cices
Chronic Spontaneous Urticaria, CSU
05/26
06/26
NCT06092216: Spesolimab in Pyoderma Gangrenosum

Recruiting
2
20
US
Spesolimab
Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim
Pyoderma Gangrenosum
08/25
08/25
NCT05551793: Regeneron AA Multicenter (Dupilumab)

Recruiting
2
68
US
Dupilumab, Placebo
Emma Guttman, Regeneron Pharmaceuticals
Alopecia Areata
12/26
12/27
NCT05879458: Ritlecitinib in CTCL

Active, not recruiting
2
7
US
Ritlecitinib
Icahn School of Medicine at Mount Sinai, Pfizer
CTCL, Mycosis Fungoides, Sezary Syndrome
01/25
06/25
NCT05866562: Dupilumab in the Treatment of Pediatric Alopecia Areata

Recruiting
2
76
US
Dupilumab, Dupixent, Placebo
Icahn School of Medicine at Mount Sinai
Alopecia Areata
05/28
05/29
Papalia, Alicia
NCT05551793: Regeneron AA Multicenter (Dupilumab)

Recruiting
2
68
US
Dupilumab, Placebo
Emma Guttman, Regeneron Pharmaceuticals
Alopecia Areata
12/26
12/27
NCT06319872: The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients with Retinal Degeneration

Recruiting
1
10
US
Oral disulfiram, Antabuse
University of Rochester
Alcohol Use Disorder, Retinal Dystrophies, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
04/25
04/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Beck, Lisa
LEADS, NCT05436535: Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

Active, not recruiting
4
431
US
Dupilumab, Dupixent, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide, Hydrocortisone, Vanicream- Active, Vanicream- Experienced Dupilumab
National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
04/25
10/25
NCT05551793: Regeneron AA Multicenter (Dupilumab)

Recruiting
2
68
US
Dupilumab, Placebo
Emma Guttman, Regeneron Pharmaceuticals
Alopecia Areata
12/26
12/27
NCT06504160: Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

Recruiting
1/2
86
US
ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel
National Institute of Allergy and Infectious Diseases (NIAID), Atopic Dermatitis Research Network (ADRN), Rho Federal Systems Division, Inc., PPD, Thermo Fisher Scientific Inc.
Atopic Dermatitis
10/26
11/26
NCT04170244: Study of Skin Microbiome in AD and PS Patients

Recruiting
N/A
240
US
AD subject visit sampling procedures, PS subject visit sampling procedures, Healthy control visit sampling procedures
University of Rochester
Atopic Dermatitis, Psoriasis
04/26
04/26
Singer, Giselle
NCT06336343: Bimekizumab in Plaque Psoriasis

Recruiting
4
60
US
Bimekizumab
Icahn School of Medicine at Mount Sinai, UCB Pharma, Psoriasis Treatment Center of Central New Jersey
Plaque Psoriasis
10/25
10/25
NCT04988022: Dupilumab in the Treatment of Keloids

Active, not recruiting
4
44
US
Dupilumab, Dupixent, Placebo
Icahn School of Medicine at Mount Sinai, Regeneron Pharmaceuticals, Sanofi
Keloid
06/25
06/25
NCT05608499: Duobrii Treatment of Acne Keloidalis Nuchae (AKN)

Active, not recruiting
3
30
US
Duobrii, halobetasol propionate and tazarotene, Placebo, Bryhali, halobetasol propionate
Icahn School of Medicine at Mount Sinai, Bausch Health Americas, Inc.
Acne Keloidalis Nuchae, AKN
07/25
07/25
NCT05787860: Ruxolitinib in Seborrheic Dermatitis

Completed
2
45
US
Ruxolitinib 1.5% Cream
Icahn School of Medicine at Mount Sinai, Incyte Corporation
Seborrheic Dermatitis
01/24
01/24
NCT05399368: An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

Terminated
2
229
Canada, US
RPT193, Placebo
RAPT Therapeutics, Inc.
Atopic Dermatitis
05/24
05/24
NCT06373458: Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy

Recruiting
2
30
US
Ritlecitinib
Icahn School of Medicine at Mount Sinai, Pfizer
Keloid
03/26
05/26
NCT06532136: Deucravacitinib Rosacea

Withdrawn
2
33
US
Deucravacitinib, Placebo
Icahn School of Medicine at Mount Sinai, Bristol-Myers Squibb
Papulopustular Rosacea
01/26
01/26
NCT05549934: Ritlecitinib for Cicatricial Alopecia

Completed
2
50
US
PF-06651600, Ritlecitinib
Emma Guttman, Pfizer
Cicatricial Alopecia
03/25
03/25
NCT06013371: PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea

Terminated
2
32
US
PF-07038124, Placebo Ointment
Icahn School of Medicine at Mount Sinai, Pfizer
Seborrheic Dermatitis, Papulopustular Rosacea
02/25
02/25
NCT06795373: Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria

Recruiting
2
20
US
Ritlecitinib, PF-06651600
Ahuva D Cices
Chronic Spontaneous Urticaria, CSU
05/26
06/26
NCT06092216: Spesolimab in Pyoderma Gangrenosum

Recruiting
2
20
US
Spesolimab
Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim
Pyoderma Gangrenosum
08/25
08/25
NCT05551793: Regeneron AA Multicenter (Dupilumab)

Recruiting
2
68
US
Dupilumab, Placebo
Emma Guttman, Regeneron Pharmaceuticals
Alopecia Areata
12/26
12/27
NCT05879458: Ritlecitinib in CTCL

Active, not recruiting
2
7
US
Ritlecitinib
Icahn School of Medicine at Mount Sinai, Pfizer
CTCL, Mycosis Fungoides, Sezary Syndrome
01/25
06/25
NCT05866562: Dupilumab in the Treatment of Pediatric Alopecia Areata

Recruiting
2
76
US
Dupilumab, Dupixent, Placebo
Icahn School of Medicine at Mount Sinai
Alopecia Areata
05/28
05/29
Papalia, Alicia
NCT05551793: Regeneron AA Multicenter (Dupilumab)

Recruiting
2
68
US
Dupilumab, Placebo
Emma Guttman, Regeneron Pharmaceuticals
Alopecia Areata
12/26
12/27
NCT06319872: The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients with Retinal Degeneration

Recruiting
1
10
US
Oral disulfiram, Antabuse
University of Rochester
Alcohol Use Disorder, Retinal Dystrophies, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
04/25
04/25

Download Options